Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Faraday Pharmaceuticals is raising $30,065,949.00 in a new round of investment. Sources indicate as part of senior management Chief Financial and Business Officer, Brian Blackman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Faraday Pharmaceuticals

Faraday Pharmaceuticals is a biopharmaceutical company pursuing the development of elemental reducing agents (ERAs). This pioneering approach focuses on the ability of specific reduced forms of elements to improve outcomes for patients. Faraday Pharmaceuticals was founded in 2014 to advance the pioneering research of Mark Roth generated from his lab at the Fred Hutchinson Cancer Research Center. Faraday is headquartered in South Lake Union, Seattle.

To learn more about Faraday Pharmaceuticals, visit http://faradaypharma.com/

Contact:
Brian Blackman, Chief Financial and Business Officer
206-492-5310
bblackman@faradaypharma.com
https://www.linkedin.com/in/brian-blackman-178a41/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved